Key Takeaways
- A yeast infection is overgrowth of the fungus Candida in the vagina, and about 75 percent of women will have at least one episode in their lifetime.[3] It is not considered a sexually transmitted infection.
- Uncomplicated infection responds well to a single 150 mg oral dose of fluconazole or a short course of a topical azole, with cure rates around 80 to 90 percent.[1][2]
- Self-diagnosis is wrong more than half of the time, so confirm the diagnosis before treating, especially if symptoms persist or recur.[6]
- Recurrent infection (four or more episodes a year) affects up to 9 percent of women and is managed with long-term suppression, most classically weekly fluconazole for six months, which kept about 91 percent of women episode-free versus 36 percent on placebo.[7]
- Newer options approved by the FDA since 2021, ibrexafungerp (Brexafemme) and oteseconazole (Vivjoa), expand treatment for acute and recurrent infection.[9][10]
- Tell-tale features are intense vulvar itching, burning, and thick white clumpy discharge without odor, with a normal vaginal pH below 4.5, which is how it is distinguished from bacterial vaginosis.[1]
- See a clinician if this is your first episode, symptoms do not improve in a few days, or infections keep coming back, because those patterns can signal diabetes, resistant yeast, or another diagnosis.[18]
Here is the single most important fact about yeast infections before anything else: they are common, they are usually easy to treat, and they are frequently misdiagnosed, both by patients and by the shelf of products at the drugstore. Most women who reach for an over-the-counter antifungal do not actually have a yeast infection. In a classic multicenter study, only about 34 percent of women who self-diagnosed a yeast infection had it confirmed on laboratory testing.[6] The rest had bacterial vaginosis, a mixed infection, or no infection at all.
This guide is a physician's walk through what a yeast infection actually is, what causes it, how it is correctly diagnosed, the treatments that work, the newer medicines approved since 2021, and the home remedies that do not hold up to scrutiny. Every clinical claim is cited to a primary source, verified through the National Library of Medicine.
What Is a Yeast Infection?
A yeast infection, more precisely called vulvovaginal candidiasis (VVC), is an overgrowth of Candida, a fungus that normally lives in small numbers in the vagina and on the skin without causing problems. When the environment of the vagina shifts, Candida can multiply, transition from a harmless yeast form to an invasive filamentous (pseudohyphal) form, and trigger inflammation of the vulva and vagina.[3]
Candida albicans accounts for roughly 85 to 95 percent of uncomplicated infections. The remaining cases are caused by non-albicans species, most commonly Candida glabrata, Candida krusei, and Candida parapsilosis, which matter because they are more likely to resist the usual azole antifungals.[3][14]
The condition is extremely common. An estimated 75 percent of women will experience at least one episode of VVC in their lifetime, and roughly 40 to 50 percent will have more than one. Between 5 and 9 percent go on to develop recurrent infection, defined as four or more symptomatic episodes in a year.[3][5] A systematic review by Denning and colleagues estimated that recurrent vulvovaginal candidiasis affects about 138 million women worldwide each year.[4]
What Causes a Yeast Infection?
The vagina maintains a delicate balance of bacteria and yeast, dominated by protective Lactobacillus species that keep the environment acidic and hold Candida in check. Anything that disturbs that balance, or that suppresses the immune defenses that contain the fungus, can allow Candida to overgrow.[3]
Antibiotics
The most common trigger. Broad-spectrum antibiotics kill protective lactobacilli along with the intended target bacteria, removing the natural competition that suppresses Candida. The infection often appears after a course of antibiotics for a urinary tract infection, sinusitis, or dental infection.[18]
Elevated estrogen
Estrogen promotes Candida growth in the vagina, which is why yeast infections are more common in pregnancy, in the week before menstruation when estrogen peaks, and in women using higher-dose estrogen-containing contraceptives or hormone therapy. Yeast infections are uncommon before puberty and after menopause in women not using estrogen, a pattern that tracks with estrogen levels.[3][18]
Diabetes
Poorly controlled diabetes, especially with chronically elevated blood glucose and HbA1c, is a well-established risk factor, both because high sugar in vaginal secretions feeds the yeast and because hyperglycemia impairs immune function. Recurrent yeast infections should prompt screening for diabetes.[18]
Weakened immunity
Immunosuppression from HIV, chemotherapy, transplants, or long-term corticosteroid use raises the risk of more severe, recurrent, or difficult-to-treat infection.[2]
Lifestyle and other factors
Douching, scented hygiene products, tight non-breathable underwear, and prolonged wearing of damp clothing are commonly cited as contributors, although the evidence for each is modest. The strongest, best-documented risk factors remain antibiotics, diabetes, pregnancy, and immunosuppression.[3][18]
Yeast Infection Symptoms
The classic presentation is intense and uncomfortable:
- Vulvar and vaginal itching (pruritus), often the dominant and most bothersome symptom
- Burning of the vulva, vagina, and sometimes around the urethra
- Thick, white, clumpy discharge, often described as cottage-cheese-like, which classically has no odor
- Redness and swelling of the vulva (erythema and edema)
- Pain during sex (dyspareunia) and discomfort with urination, which is usually external burning as urine touches inflamed skin rather than internal urgency
The absence of a strong fishy odor is a useful clue. A malodorous, thin discharge points instead toward bacterial vaginosis or trichomoniasis.[1]
How Is a Yeast Infection Diagnosed?
Diagnosis combines symptoms with simple office testing, and the two key findings are the pH of vaginal fluid and the appearance of Candida under a microscope.[1][21]
Vaginal pH. In a yeast infection, the vaginal pH stays in the normal acidic range, below 4.5. In bacterial vaginosis and trichomoniasis, the pH rises above 4.5. This single measurement separates the two most commonly confused conditions.[1]
Microscopy. A sample of discharge mixed with potassium hydroxide (KOH) is examined under a microscope. The KOH dissolves human cells so the fungus is easier to see. The finding of budding yeast and thread-like pseudohyphae confirms candidiasis.[21]
Culture or DNA testing is reserved for cases that do not respond to treatment or keep recurring, when identifying the exact species and its drug sensitivity guides therapy, particularly for non-albicans species that resist azoles.[2]
Because home diagnosis is so unreliable, guidelines emphasize confirming the diagnosis rather than treating empirically, especially for anything beyond a first, classic episode.[6]
Yeast Infection vs BV and Other Vaginitis
Three conditions cause most vaginal discharge and irritation: yeast infection, bacterial vaginosis (BV), and trichomoniasis. They are treated with entirely different medicines, so telling them apart matters. The table below summarizes the distinguishing features.
| Feature | Yeast infection (VVC) | Bacterial vaginosis (BV) | Trichomoniasis |
|---|---|---|---|
| Predominant symptom | Itching and burning | Mild or no discomfort | Irritation, soreness |
| Discharge | Thick, white, clumpy, no odor | Thin, gray-white, fishy odor | Frothy, yellow-green |
| Vaginal pH | Below 4.5 (normal) | Above 4.5 | Above 4.5 |
| Cause | Candida fungus | Bacterial overgrowth | Parasite (T. vaginalis) |
| Key treatment | Azole antifungal vs. fluconazole | Metronidazole or clindamycin | Metronidazole or tinidazole |
| Sexually transmitted | No | Not strictly, but associated with sex | Yes |
For a full side-by-side breakdown of how to tell a yeast infection from BV, see our dedicated guide on yeast infection vs BV and the companion bacterial vaginosis guide. Vaginal dryness, common after menopause, can also cause burning and irritation and belongs in the differential; see the vaginal dryness treatment guide.
What's Changed 2024 to 2026
Three developments have updated the picture for patients and clinicians:
- New FDA-approved oral antifungals. Ibrexafungerp (Brexafemme), approved in 2021, is the first oral non-azole for acute VVC and was shown in its phase 3 trial to outperform placebo, with roughly 50 percent of treated women achieving clinical cure at day 10.[9] Oteseconazole (Vivjoa), approved in 2022, is a newer azole indicated for recurrent infection.[10]
- Monthly ibrexafungerp for prevention. The 2025 CANDLE trial showed that a monthly 300 mg dose of ibrexafungerp significantly reduced recurrent episodes compared with placebo, expanding options for women who relapse on weekly fluconazole.[11]
- Growing attention to azole resistance. A 2026 state-of-the-art review and a 2024 update both flag rising azole resistance, especially in non-albicans species, as the key emerging clinical issue, with boric acid and the newer agents as the main fallbacks.[8][14]
Which Treatment Is Right for You
Treatment choice depends on whether the infection is classified as uncomplicated or complicated, a distinction formalized in the IDSA guideline.[2]
| Scenario | Definition | Recommended approach |
|---|---|---|
| Uncomplicated VVC | Mild to moderate, sporadic, healthy non-pregnant woman, C. albicans, pH below 4.5 | Any short-course topical azole (1 to 7 days) or a single 150 mg oral fluconazole dose[1] |
| Severe VVC | Extensive erythema, edema, excoriation or fissures | Topical azole for 7 to 14 days or fluconazole 150 mg every 72 hours for two or three doses[1][2] |
| Recurrent VVC | Four or more episodes in 12 months | Induction followed by suppression, classically weekly fluconazole for 6 months[7] |
| Non-albicans or azole-resistant | C. glabrata or fluconazole failure | Boric acid capsules, topical agents, or specialist referral[13][14] |
| Pregnancy | Any episode during pregnancy | Topical clotrimazole or miconazole for 7 days only; avoid oral fluconazole[1] |
Treatment: The Evidence
The mainstay of treatment is the azole class of antifungals, which interfere with the fungal cell wall by blocking ergosterol synthesis. They come as short-course topical creams and suppositories (miconazole, clotrimazole, tioconazole, and the prescription terconazole) and as the oral option fluconazole.[1][2]
Oral fluconazole 150 mg as a single dose is convenient, widely used, and roughly as effective as topical therapy for uncomplicated infection. In head-to-head studies it performed about as well as intravaginal terconazole and clotrimazole.[16][17] The single-dose convenience makes it a common choice for women who prefer a pill and can take an oral medication.[22]
Topical azoles avoid systemic drug exposure and are preferred in pregnancy. Miconazole and clotrimazole are available over the counter in 1-day, 3-day, and 7-day courses, and terconazole 0.4 percent or 0.8 percent is prescription only. Longer courses (7 days) are generally recommended for more severe symptoms and in pregnancy.[1]
Ibrexafungerp is an oral triterpenoid antifungal (not an azole) that blocks glucan synthase. It is taken as two 150 mg tablets every 12 hours for one day (two doses total) and offers an option when azoles are not suitable. In its phase 3 trial it produced clinical cure in about half of treated women versus roughly a third on placebo at day 10.[9][23]
Oteseconazole is a long-acting oral azole approved specifically for recurrent VVC, taken in a short induction course followed by weekly dosing. In its trial it markedly reduced recurrence compared with fluconazole followed by placebo.[10] Earlier phase 2 data showed a single dose of the same molecule produced clinical cure in a majority of women with acute infection.[12]
Comparison: Topical Azoles vs Oral Fluconazole
| Option | Route / dosing | Availability | Typical cure rate | Notes |
|---|---|---|---|---|
| Fluconazole 150 mg | Oral, single dose | Prescription (generic) | 80 to 90 percent[1] | Most convenient; avoid in pregnancy |
| Miconazole | Vaginal, 1 to 7 days | OTC | 80 to 90 percent[1] | Messy but effective; safe in pregnancy |
| Clotrimazole | Vaginal, 3 to 7 days | OTC | 80 to 90 percent[1] | Common first choice; safe in pregnancy |
| Terconazole | Vaginal, 3 to 7 days | Prescription | Comparable to fluconazole[16] | Strong topical option |
| Ibrexafungerp | Oral, 2 doses over 1 day | Prescription | Clinical cure about 50 percent[9] | Non-azole oral alternative |
A 2025 review in the American Journal of Obstetrics and Gynecology concluded that topical and oral agents reach similar overall outcomes for uncomplicated VVC and that the choice is largely patient preference, a finding consistent with earlier head-to-head trials.[15][16]
How Long Does a Yeast Infection Last?
With treatment, symptoms usually begin to improve within 24 to 48 hours, and most uncomplicated infections clear within a week. The single-dose topical (1-day) regimens are convenient but sometimes clear symptoms a bit more slowly than the multi-day topical courses in some studies, even if final outcomes are similar.[15] Untreated, a mild infection can sometimes resolve on its own, but it usually persists or worsens and should be treated, especially with bothersome symptoms.[2]
Recurrent Yeast Infections
Recurrent vulvovaginal candidiasis is defined as four or more culture-proven episodes in a year. It reflects a host predisposition rather than a persisted infection that was never cured; in most recurrent cases the Candida strain is the woman's own, and relapse occurs from the same reservoir.[8]
The best-established management is induction treatment to clear the current episode, followed by maintenance suppression. In the landmark 2004 New England Journal of Medicine trial by Sobel and colleagues, weekly oral fluconazole 150 mg for six months kept 90.8 percent of women free of recurrence at six months, compared with 35.9 percent on placebo. The benefit persisted only while taking the medication; after stopping, relapse rates in the two groups converged over the following months, underscoring that suppression controls rather than cures the tendency.[7]
For women who relapse despite weekly fluconazole, or who harbor azole-resistant or non-albicans species, options include induction followed by oteseconazole, boric acid vaginal capsules, or specialist evaluation.[10][13][14] Our recurrent yeast infection guide covers this in full depth.
Side Effects and Safety
Topical azoles occasionally cause local burning or irritation at the application site and are otherwise very well tolerated.[1]
Oral fluconazole can cause headache, nausea, and abdominal discomfort, and rarely elevates liver enzymes. It carries a number of drug interactions, most importantly with warfarin, certain statins, and several anti-seizure and heart-rhythm medicines, and it is not recommended in pregnancy, particularly in the first trimester, because of a possible small increased risk of birth defects and miscarriage with high or repeated doses.[22] The FDA prescribing information notes the pregnancy cautions and interaction profile.[22]
Treatment of a male sex partner is not recommended, because yeast infection is not considered a sexually transmitted infection and partner treatment does not reduce recurrence.[1]
Yeast Infection in Pregnancy
Yeast infections are more common in pregnancy because of higher estrogen. The CDC recommends only topical azoles, specifically clotrimazole or miconazole, for seven days, and advises against oral fluconazole in pregnancy, especially in the first trimester.[1] Among topical agents studied in pregnancy, sertaconazole has also been shown to be effective and safe in a randomized trial against clotrimazole.[25] A large cross-sectional study confirmed candidiasis is frequent in pregnancy and that susceptibility testing matters for persistent symptoms.[24]
Prevention
Evidence-based prevention focuses on the risk factors you can change:
- Use antibiotics only when needed. Avoid unnecessary antibiotic courses, the most common trigger.[18]
- Keep diabetes controlled. Tight glucose control reduces recurrence in women with diabetes.[18]
- Skip douching and scented products. They disrupt the normal vaginal flora.[3]
- Wear breathable clothing. Cotton underwear and avoiding prolonged wet or tight clothing may help, though the evidence is modest.[3]
- Consider probiotics. A Cochrane review found that adding probiotics to antifungal therapy may modestly reduce the chance of recurrence in some women, but the certainty of evidence is low and probiotics cannot replace treatment.[20]
What Doesn't Work
Several popular remedies lack evidence or can make things worse:
- Douching with anything. No douche treats yeast; douching disrupts protective flora and may drive infection upward.
- Yogurt applied to the vagina. Despite folklore, direct application of yogurt is not a validated treatment, and the evidence for any benefit is weak.[20]
- Garlic cloves inserted vaginally. Not proven effective and can cause burns or chemical irritation.
- Apple cider vinegar. No clinical evidence, and vinegar is more likely to irritate inflamed tissue than to help.
- Tea tree oil. Has some laboratory activity against Candida but little clinical trial support and can cause contact irritation.
For a detailed, sourced breakdown of what the evidence says about these and other home approaches, see the yeast infection home remedies guide.
Red Flags: When to Contact a Clinician
See a clinician rather than self-treating when any of these apply:
- This is your first suspected yeast infection
- Symptoms do not improve within a few days of over-the-counter treatment
- You have a fever, chills, pelvic pain, or a foul-smelling discharge
- Infections return repeatedly, four or more times a year
- You are pregnant or breastfeeding
- You have diabetes, HIV, or another immunocompromising condition, or take immunosuppressive medicines
- You have pain with urination that feels internal, flank pain, or any symptom suggesting a urinary tract infection or pelvic inflammatory disease
These patterns can indicate a resistant or non-albicans infection, an undiagnosed condition such as diabetes, or an entirely different diagnosis that needs different treatment.[18][19]
Frequently Asked Questions
A yeast infection typically causes redness and swelling of the vulva with thick, white, clumpy discharge that resembles cottage cheese and has little or no odor. The dominant symptom is intense itching and burning. Discharge from bacterial vaginosis, by contrast, is thin and gray-white with a fishy odor.[1]
Yes, uncomplicated infection can be treated with OTC miconazole or clotrimazole, but confirm the diagnosis is actually a yeast infection first. More than half of women who self-diagnose are wrong, so if this is a first episode or symptoms are unusual, see a clinician.[6]
With treatment, symptoms usually begin improving within 24 to 48 hours and resolve within about a week. Untreated infections can persist or worsen and should be treated.[15]
Occasionally a very mild infection may resolve without treatment as the vaginal flora rebalances, but this is unreliable, and most symptomatic infections persist or worsen. Treatment clears symptoms faster and more reliably.[2]
No. Yeast infection is not classified as a sexually transmitted infection, and treating a male partner is not recommended because it does not reduce recurrence. The fungus is normally present in the vagina and overgrows when conditions change.[1]
Yes. Men can develop a yeast infection, usually on the glans of the penis (balanitis), with redness, itching, and irritation, though it is far less common than in women. Risk factors include diabetes, an uncircumcised penis, and immunosuppression.[3]
Yes, with topical clotrimazole or miconazole for seven days, which are considered safe in pregnancy. Oral fluconazole is generally avoided in pregnancy, particularly in the first trimester. Always discuss treatment with your obstetrician.[1]
The direct role of stress and dietary sugar is not firmly established. The strongest documented triggers are antibiotics, diabetes, pregnancy, and immune suppression. High blood sugar from poorly controlled diabetes is the relevant dietary link, not occasional sweets.[18]
There is limited, low-certainty evidence that probiotics, taken alongside antifungal treatment, may modestly reduce recurrence. They should not be used as a substitute for antifungal therapy.[20]
References
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1
- Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50. doi:10.1093/cid/civ933
- Gonçalves B, Ferreira C, Alves CT, Henriques M, et al. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016;42(6):905-927. doi:10.3109/1040841X.2015.1091805
- Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(10):e339-e347. doi:10.1016/S1473-3099(18)30103-8
- Foxman B, Muraglia R, Dietz JP, Sobel JD. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from the first global systematic survey. J Low Genit Tract Dis. 2013;17(1):45-52. doi:10.1097/LGT.0b013e318273e8cf
- Ferris DG, Nyirjesy P, Sobel JD, et al. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol. 2002;99(3):419-425. doi:10.1016/s0029-7844(01)01759-8
- Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351(9):876-883. doi:10.1056/NEJMoa033114
- Rautemaa-Richardson R, Sobel JD, Stone N, et al. State-of-the-Art Review: Managing Vulvovaginal Candidiasis. Clin Infect Dis. 2026. doi:10.1093/cid/ciaf673
- Schwebke JR, Sobel R, Gersten JK, et al. Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). Clin Infect Dis. 2022;74(11):1979-1985. doi:10.1093/cid/ciab750
- Sobel JD, Donders G, Degenhardt T, et al. Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis. NEJM Evid. 2022;1(8):EVIDoa2100055. doi:10.1056/EVIDoa2100055
- Goje O, Azie NE, Angulo DA, et al. A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (CANDLE). Am J Obstet Gynecol. 2025. doi:10.1016/j.ajog.2025.07.040
- Brand SR, Sobel JD, Nyirjesy P, Ghannoum MA. A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis. Clin Infect Dis. 2021;73(7):e1518-e1524. doi:10.1093/cid/ciaa1204
- Iavazzo C, Gkegkes ID, Zarkada IM, Falagas ME. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health (Larchmt). 2011;20(8):1245-1255. doi:10.1089/jwh.2010.2708
- Akinosoglou K, Livieratos A, Asimos K, et al. Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management. Pharmaceutics. 2024;16(12):1555. doi:10.3390/pharmaceutics16121555
- Gardella B, Dominoni M, Cassani C, et al. Treatment of uncomplicated vulvovaginal candidiasis: topical or oral drugs? Am J Obstet Gynecol. 2025. doi:10.1016/j.ajog.2025.03.031
- Slavin MB, Benrubi GI, Parker R, Griffin CR. Single dose oral fluconazole vs intravaginal terconazole in treatment of Candida vaginitis. J Fla Med Assoc. 1992;79(10):693-696. PMID 1460451
- Mikamo H, Matsumizu M, Nakazuru Y, Okayama A. Efficacy and safety of a single oral 150 mg dose of fluconazole for the treatment of vulvovaginal candidiasis. J Infect Chemother. 2015;21(9):652-656. doi:10.1016/j.jiac.2015.03.011
- Patel DA, Gillespie B, Sobel JD, et al. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy. Am J Obstet Gynecol. 2004;190(3):644-653. doi:10.1016/j.ajog.2003.11.027
- Crouss T, Sobel JD, Smith K, Nyirjesy P. Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Antifungal Therapy. J Low Genit Tract Dis. 2018;22(4):298-302. doi:10.1097/LGT.0000000000000413
- Xie HY, Feng D, Wei DM, et al. Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database Syst Rev. 2017;11(11):CD010496. doi:10.1002/14651858.CD010496.pub2
- Abbott J. Clinical and microscopic diagnosis of vaginal yeast infection: a prospective analysis. Ann Emerg Med. 1995;25(5):587-591. doi:10.1016/s0196-0644(95)70168-0
- U.S. Food and Drug Administration. Diflucan (fluconazole) prescribing information. FDA label
- Phillips NA, Rocktashel M, Merjanian L. Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy. Drug Des Devel Ther. 2023;17:363-367. doi:10.2147/DDDT.S339349
- Hussen I, Aliyo A, Abbai MK, Dedecha W. Vaginal candidiasis prevalence, associated factors, and antifungal susceptibility patterns among pregnant women. BMC Pregnancy Childbirth. 2024;24. doi:10.1186/s12884-024-06844-x
- Chayachinda C, Thamkhantho M, Rekhawasin T, Klerdklinhom C. Sertaconazole 300 mg versus clotrimazole 500 mg vaginal suppository for treating vulvovaginal candidiasis in pregnant women: a randomized controlled trial. BMC Pregnancy Childbirth. 2024;24. doi:10.1186/s12884-024-06440-z